Verastem (VSTM) News Today → What is Medicare Supplement Insurance? (From Tranzact) (Ad) Free VSTM Stock Alerts $9.22 -0.10 (-1.07%) (As of 04/25/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineVerastem (NASDAQ:VSTM) Share Price Crosses Above 200-Day Moving Average of $9.60americanbankingnews.com - April 23 at 3:20 AMVerastem Oncology appoints new CMO to lead cancer drug trialsinvesting.com - April 20 at 11:47 PMVerastem, Inc. (VSTM)finance.yahoo.com - April 19 at 8:05 PMVerastem Oncology Names John Hayslip as Chief Medical Officermarketwatch.com - April 18 at 7:05 PMVerastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officerbusinesswire.com - April 18 at 4:05 PMAnalysts Offer Insights on Healthcare Companies: Shattuck Labs (STTK) and Verastem (VSTM)markets.businessinsider.com - April 12 at 5:19 PMVerastem (NASDAQ:VSTM) Share Price Passes Above 200-Day Moving Average of $9.47marketbeat.com - April 12 at 2:18 AMVerastem CFO sells shares to cover tax obligationsinvesting.com - April 10 at 1:47 PMVerastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)businesswire.com - April 4 at 7:30 AMVerastem, Inc. (NASDAQ:VSTM) Receives Average Rating of "Buy" from Analystsmarketbeat.com - April 4 at 2:16 AMVerastem’s Strategic Advancements and Financial Stability Underscore Buy Ratingmarkets.businessinsider.com - March 27 at 7:36 PMVerastem director sells over $8,500 in company stockinvesting.com - March 22 at 8:04 PMVSTM Apr 2024 11.000 callfinance.yahoo.com - March 20 at 4:57 AMVerastem: Financial Resilience and Promising Drug Pipeline Despite Short-Term Lossesmarkets.businessinsider.com - March 19 at 1:14 PMVerastem's (VSTM) "Buy" Rating Reiterated at HC Wainwrightmarketbeat.com - March 19 at 8:34 AMRoyal Bank of Canada Reiterates Outperform Rating for Verastem (NASDAQ:VSTM)marketbeat.com - March 18 at 5:44 PMGlobal Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancerbusinesswire.com - March 18 at 7:00 AMVSTM Apr 2024 14.000 callfinance.yahoo.com - March 16 at 8:52 AMRecap: Verastem Q4 Earningsbenzinga.com - March 14 at 10:18 PMVSTM Stock Earnings: Verastem Misses EPS for Q4 2023investorplace.com - March 14 at 10:04 PMVerastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updatesbusinesswire.com - March 14 at 4:05 PMVerastem (NASDAQ:VSTM) Downgraded by StockNews.com to Sellmarketbeat.com - March 12 at 11:14 PMVerastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needsfinance.yahoo.com - March 11 at 8:25 AMVerastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women's Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needsbusinesswire.com - March 11 at 7:30 AMVSTM Mar 2024 2.000 putfinance.yahoo.com - March 10 at 7:50 PMAdage Capital Partners GP L.L.C. Grows Stock Holdings in Verastem, Inc. (NASDAQ:VSTM)marketbeat.com - March 9 at 6:36 AMVerastem Oncology Granted FDA Orphan Drug Designation For Avutometinib In Ovarian Cancermarkets.businessinsider.com - March 6 at 6:41 PMVerastem gets FDA orphan drug status for low-grade ovarian cancer therapymsn.com - March 6 at 6:41 PM203,327 Shares in Verastem, Inc. (NASDAQ:VSTM) Acquired by Sectoral Asset Management Inc.marketbeat.com - March 6 at 10:15 AMVerastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancerbusinesswire.com - March 5 at 5:27 PMVerastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024businesswire.com - March 5 at 4:30 PMVerastem (NASDAQ:VSTM) Stock Price Crosses Above Two Hundred Day Moving Average of $9.10marketbeat.com - March 2 at 3:14 AMVerastem Stock (NASDAQ:VSTM), Short Interest Reportbenzinga.com - February 23 at 5:02 AMVerastem (NASDAQ:VSTM) Stock Price Crosses Above Two Hundred Day Moving Average of $9.00marketbeat.com - February 23 at 4:14 AMAndreas Halvorsen's Viking Global Investors LP Bolsters Position in Verastem Incfinance.yahoo.com - February 15 at 7:54 AMStockNews.com Upgrades Verastem (NASDAQ:VSTM) to "Hold"marketbeat.com - February 15 at 1:30 AMVerastem, Inc. (NASDAQ:VSTM) Given Consensus Recommendation of "Buy" by Brokeragesmarketbeat.com - February 14 at 1:53 AMShort Interest in Verastem, Inc. (NASDAQ:VSTM) Grows By 21.9%marketbeat.com - February 13 at 10:47 AMDirector Robert Gagnon Sells 9,204 Shares of Verastem Inc (VSTM)finance.yahoo.com - February 7 at 10:05 PMVerastem: Other Catalysts In 2024 Beyond NDA Rolling Submission Of Defactinibseekingalpha.com - February 7 at 12:05 PMBuy Rating on Verastem: Strategic Execution and Promising Drug Pipeline Signal Market Opportunitymarkets.businessinsider.com - January 30 at 4:40 AMVerastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancersfinance.yahoo.com - January 29 at 7:22 AMVerastem Shareholders Approve Executive Option Exchange Planmsn.com - January 20 at 7:44 AMVerastem, Inc. (NASDAQ:VSTM) Receives Average Recommendation of "Buy" from Analystsmarketbeat.com - January 20 at 2:26 AMVerastem Gets FDA Fast-Track Approval on Lung Cancer Treatmentmarketwatch.com - January 19 at 8:49 PMFDA grants fast track designation for Verastem’s NSCLC therapymsn.com - January 19 at 10:48 AMVerastem : Avutometinib Combination Receives Fast Track Designation For KRAS G12C-Mutant NSCLCmarkets.businessinsider.com - January 18 at 10:57 PMVerastem gets FDA fast track status for lung cancer drug combomsn.com - January 18 at 5:56 PMVerastem Oncology Granted Fast Track Designation for Combination of Avutometinib and Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)finance.yahoo.com - January 18 at 5:56 PMStockNews.com Downgrades Verastem (NASDAQ:VSTM) to Sellmarketbeat.com - January 15 at 10:15 PM Get Verastem News Delivered to You Automatically Sign up to receive the latest news and ratings for VSTM and its competitors with MarketBeat's FREE daily newsletter. Email Address Claim Your Complimentary Bitcoin Reward (Ad)Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached. Secure Your Spot Now VSTM Media Mentions By Week VSTM Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VSTM News Sentiment▼-0.320.36▲Average Medical News Sentiment VSTM News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VSTM Articles This Week▼42▲VSTM Articles Average Week Get Verastem News Delivered to You Automatically Sign up to receive the latest news and ratings for VSTM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: XOMA News Vanda Pharmaceuticals News Rigel Pharmaceuticals News Regulus Therapeutics News Lexicon Pharmaceuticals News Emergent BioSolutions News OPKO Health News Innoviva News MannKind News Nektar Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VSTM) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTrump is sounding the alarmPreserve GoldFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verastem, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
